Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06658067 · ClinicalTrials.gov registry record · NA

Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access

A NA study of Diabetes and Type 2 Diabetes, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT06658067 is a NA study of Diabetes and Type 2 Diabetes that is actively recruiting participants, run by Yale University. The registered enrollment target is 17 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06658067, a NA study of Diabetes and Type 2 Diabetes, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This non-blinded, non-randomized pre-post study will examine the impact of providing CGM sensors free of charge to adult patients of Fair Haven Community Health Care with poorly controlled type 2 diabetes on glycemic control and quality of life.

Interventions

  • DEVICE Continuous Glucose Monitor (CGM)

Study Locations (1)

Connecticut

  • Fair Haven Community Health Care (FHCHC) - New Haven

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2024-11-12
Est. Completion 2026-06
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT06658067

The ClinicalTrials.gov registry entry for NCT06658067 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Continuous Glucose Monitor (CGM) is the first listed.

NCT06658067 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT06658067 about?

NCT06658067 is a clinical study titled "Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access". This non-blinded, non-randomized pre-post study will examine the impact of providing CGM sensors free of charge to adult patients of Fair Haven Community Health Care with poorly controlled type 2 diabetes on glycemic control and quality of life.

What is the current status of trial NCT06658067?

This trial is currently recruiting. It is a NA study. The enrollment target is 17 participants. The study started on 2024-11-12. Estimated completion is 2026-06.

What conditions does trial NCT06658067 study?

This clinical trial studies the following conditions: Diabetes, Type 2 Diabetes, Type 2 Diabetes Mellitus - Poor Control.

What interventions are being tested in trial NCT06658067?

The interventions under investigation include: Continuous Glucose Monitor (CGM) (DEVICE).

Who is sponsoring clinical trial NCT06658067?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06658067 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.